According to the latest data from the National Health Commission's Department of Maternal and Child Health, there are currently 602 medical institutions nationwide that have been approved to carry out human assisted reproductive technology, with the number of IVF institutions globally continuing to increase. These institutions mainly use computer-assisted sperm analysis (CASA) methods based on the fifth edition of the WHO guidelines to analyze sperm quantity, vitality, morphology, and other aspects.

Looking at the market size, data from Zhongyin Consulting shows that the market size of sperm quality analyzers in China will continue to expand in the coming years. In 2023, the market size was close to 0.3 billion yuan, while the global market size for sperm analyzers reached as high as 0.4 billion US dollars. It is worth anticipating that with a compound annual growth rate of 10%, by 2026, the global market size will exceed 0.5 billion US dollars. This is a market with huge potential, like an untapped gold mine, full of opportunities.

However, traditional CASA sperm detection technology has significant limitations. On one hand, its reliability and repeatability are poor, and it is unable to detect the morphology of live sperm. On the other hand, CASA requires staining of sperm samples and relies on manual operations during the process, not only increasing the complexity of the test but also possibly altering the morphology of the sperm during the staining process, thereby affecting the accuracy of the test results. To address these pain points, Becon Medical, in collaboration with 18 top domestic centers, has launched the largest nationwide AI sperm detection research, comparing and clinically verifying detailed analysis of 500,000 sperm samples, developing automated live sperm detection technology aiming to overcome the limitations of traditional CASA technology, improving the accuracy and efficiency of sperm detection.

Furthermore, when using traditional CASA technology, patients need to visit the hospital at least twice, sometimes even waiting a week to receive the test report. In contrast, Becon Medical's intelligent sperm quality analyzer uses AI technology for analysis, eliminating the need for staining of sperm samples, and can complete analysis of unstained live sperm morphology, concentration, and vitality in as fast as 3 minutes. Patients only need one test to find qualified sperm for embryo culture, greatly optimizing the patient's service experience. By reducing the number of tests and shortening waiting time, Becon's sperm analyzer not only improves patient satisfaction but also significantly increases hospital work efficiency, shortening the overall duration of IVF cycles.

The latest announcement shows that Beckon Medical's intelligent sperm quality analyzer (BKA210) has recently been approved for listing (Suichuang Approval: 20242222101), making it the world's first device capable of detecting unstained living sperm. This equipment, with its domestically pioneered and internationally leading innovative technology, has been awarded the National Disruptive Technological Innovation Excellent Project Award by the country, indicating high recognition from both the national and clinical experts. From Beckon's interim earnings reports, it can be seen that it has received a large number of orders in the andrology laboratory setting, and now the commercial strength verified is not to be underestimated.

Overall, with the sperm quality analyzer recently approved by Beckon Medical, along with the company's globally leading wet Geri full-time incubator, and the iARMS intelligent assisted reproduction management system, it is gradually constructing a comprehensive intelligent assisted reproduction center ecosystem. As Beckon Medical continues to strengthen its andrology product line, the company is directly enhancing clinical test results from the product side, dedicated to creating truly innovative and competitive products. This innovation not only improves the accuracy and efficiency of testing but is also expected to significantly enhance performance and translate into sales growth. Additionally, Beckon Medical's sperm quality analyzer is in the process of applying for CE certification in the European market. It is expected to expand its global market further after obtaining certification by the end of the year, continuing to make positive contributions to fertility health endeavors in China and globally.